Share Facebook Twitter Email This cross-sectional study of claims data in D.C. demonstrates sharp declines in routine screenings for breast (-40%), cervical (-36%) and colon (-45%) cancers early in the pandemic with only a partial rebound thereafter. Oakes, JAMA Oncol 2022